Related references
Note: Only part of the references are listed.A benchmark for dose-finding studies with unknown ordering
Pavel Mozgunov et al.
BIOSTATISTICS (2022)
Practical recommendations for implementing a Bayesian adaptive phase I design during a pandemic
Sean Ewings et al.
BMC MEDICAL RESEARCH METHODOLOGY (2022)
Bayesian dose regimen assessment in early phase oncology incorporating pharmacokinetics and pharmacodynamics
Emma Gerard et al.
BIOMETRICS (2022)
A dose-finding design for dual-agent trials with patient-specific doses for one agent with application to an opiate detoxification trial
Pavel Mozgunov et al.
PHARMACEUTICAL STATISTICS (2022)
A straightforward meta-analysis approach for oncology phase I dose-finding studies
Christian Roever et al.
STATISTICS IN MEDICINE (2022)
Using an Interaction Parameter in Model-Based Phase I Trials for Combination Treatments? A Simulation Study
Pavel Mozgunov et al.
INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH (2021)
Phase I dose-escalation oncology trials with sequential multiple schedules
Burak Kuersad Guenhan et al.
BMC MEDICAL RESEARCH METHODOLOGY (2021)
Phase I/II trial of a long peptide vaccine (LPV7) plus toll-like receptor (TLR) agonists with or without incomplete Freund's adjuvant (IFA) for resected high-risk melanoma
Sapna P. Patel et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Designing and evaluating dose-escalation studies made easy: The MoDEsT web app
Philip Pallmann et al.
CLINICAL TRIALS (2020)
Improving safety of the continual reassessment method via a modified allocation rule
Pavel Mozgunov et al.
STATISTICS IN MEDICINE (2020)
A surface-free design for phase I dual-agent combination trials
Pavel Mozgunov et al.
STATISTICAL METHODS IN MEDICAL RESEARCH (2020)
A comparison of phase I dose-finding designs in clinical trials with monotonicity assumption violation
Rachid Abbas et al.
CLINICAL TRIALS (2020)
A Bayesian time-to-event pharmacokinetic model for phase I dose-escalation trials with multiple schedules
Burak Kuersad Guenhan et al.
STATISTICS IN MEDICINE (2020)
An information theoretic approach for selecting arms in clinical trials
Pavel Mozgunov et al.
JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES B-STATISTICAL METHODOLOGY (2020)
An information theoretic phase I-II design for molecularly targeted agents that does not require an assumption of monotonicity
Pavel Mozgunov et al.
JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES C-APPLIED STATISTICS (2019)
How to design a dose-finding study using the continual reassessment method
Graham M. Wheeler et al.
BMC MEDICAL RESEARCH METHODOLOGY (2019)
The Impact of Early-Phase Trial Design in the Drug Development Process
Mark R. Conaway et al.
CLINICAL CANCER RESEARCH (2019)
A web tool for designing and conducting phase I trials using the continual reassessment method
Nolan A. Wages et al.
BMC CANCER (2018)
Dose Transition Pathways: The Missing Link Between Complex Dose-Finding Designs and Simple Decision-Making
Christina Yap et al.
CLINICAL CANCER RESEARCH (2017)
Implementing the EffTox dose-finding design in the Matchpoint trial
Kristian Brock et al.
BMC MEDICAL RESEARCH METHODOLOGY (2017)
Embracing model-based designs for dose-finding trials
Sharon B. Love et al.
BRITISH JOURNAL OF CANCER (2017)
On the Use of Co-Data in Clinical Trials
Beat Neuenschwander et al.
STATISTICS IN BIOPHARMACEUTICAL RESEARCH (2016)
Statistical controversies in clinical research: requiem for the 3+3 design for phase I trials
X. Paoletti et al.
ANNALS OF ONCOLOGY (2015)
A Phase I/II adaptive design to determine the optimal treatment regimen from a set of combination immunotherapies in high-risk melanoma
Nolan A. Wages et al.
CONTEMPORARY CLINICAL TRIALS (2015)
The future of immune checkpoint therapy
Padmanee Sharma et al.
SCIENCE (2015)
A comparative study of adaptive dose-finding designs for phase I oncology trials of combination therapies
Akihiro Hirakawa et al.
STATISTICS IN MEDICINE (2015)
Designs of drug-combination phase I trials in oncology: a systematic review of the literature
M. -K. Riviere et al.
ANNALS OF ONCOLOGY (2015)
A likelihood-based approach for computing the operating characteristics of the 3+3 phase I clinical trial design with extensions to other A plus B designs
Cody Chiuzan et al.
CLINICAL TRIALS (2015)
Competing designs for drug combination in phase I dose-finding clinical trials
M. -K. Riviere et al.
STATISTICS IN MEDICINE (2015)
Comments on 'Competing designs for drug combination in phase I dose-finding clinical trials' by M-K. Riviere, F. Dubois, S. Zohar
Nolan A. Wages
STATISTICS IN MEDICINE (2015)
A Bayesian dose-finding design for drug combination clinical trials based on the logistic model
Marie-Karelle Riviere et al.
PHARMACEUTICAL STATISTICS (2014)
Phase I design for completely or partially ordered treatment schedules
Nolan A. Wages et al.
STATISTICS IN MEDICINE (2014)
bcrm: Bayesian Continual Reassessment Method Designs for Phase I Dose-Finding Trials
Michael Sweeting et al.
JOURNAL OF STATISTICAL SOFTWARE (2013)
Specifications of a continual reassessment method design for phase I trials of combined drugs
Nolan A. Wages et al.
PHARMACEUTICAL STATISTICS (2013)
Continual Reassessment Method for Partial Ordering
Nolan A. Wages et al.
BIOMETRICS (2011)
A comprehensive comparison of the continual reassessment method to the standard 3+3 dose escalation scheme in Phase I dose-finding studies
Alexia Iasonos et al.
CLINICAL TRIALS (2008)
Share Paper
